SIDE EFFECTS
OF ONCOLYTIC VIRUS THERAPY
T-VEC side effects differ fundamentally from chemotherapy. Flu-like symptoms (20–30% of patients, 24–72 hours post-injec
Expected Side Effects vs. When to Call
One distinction determines how patients manage T-VEC at home more than any other: expected injection site and systemic effects versus signs of viral spread requiring immediate contact.
Expected — No Call Needed
Lesion enlargement, redness, induration, swelling, pain, occasional ulceration at injection sites. Fatigue, low-grade fever, chills, myalgia for 24–72 hours post-injection. These are the treatment mechanism made visible.
Report Same Day
Vesicular rash spreading beyond the injection site boundary. Fever above 38°C. Anything suggesting viral spread past the treated area. Signs of bacterial cellulitis: increasing warmth, spreading erythema, purulent drainage.
T-VEC Side Effects at a Glance
- 20–30%Patients with flu-like symptoms post-injectionDiminishes with successive treatments.
- 24–72 hrsDuration of systemic symptomsPredictable cycling, clears before next treatment.
- 0%Myelosuppression or alopeciaThese are absent from the T-VEC toxicity profile.
What T-VEC Does NOT Cause
Patients expecting chemotherapy toxicity are surprised. The absence of these effects is real and clinically meaningful.
No Myelosuppression
No bone marrow suppression, no neutropenia, no need for growth factor support or transfusion planning.
No Alopecia
Hair loss is not part of the T-VEC toxicity profile.
No Severe Nausea or Mucositis
Significant nausea requiring antiemetics and mouth sores are not T-VEC toxicities.
No Peripheral Neuropathy
Chemotherapy-related nerve damage does not occur with T-VEC.
Frequently Asked Questions
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination — travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
Questions About T-VEC Side Effects?
CancerFax connects patients with specialist centres experienced in T-VEC management and supports patients through the full treatment cycle.
This content is for informational purposes only and does not constitute medical advice. Always consult a qualified oncologist before making treatment decisions.